To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00482196

Enrollment

173

Registered

2007-06-05

Start date

2005-07-31

Completion date

2006-03-31

Last updated

2015-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Interventions

DRUGMK0493

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patient is between 21 and 65 years of age

Exclusion criteria

* HIV positive as determined by medical history * Patient is pregnant, lactating or plans to become pregnant * Patient has undergone surgical treatment for obesity * Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study * Patient plans to consume more than 2 glasses of grapefruit juice per day during the study * Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026